Simplify Asset Management Inc. Makes New $833,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Simplify Asset Management Inc. purchased a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 120,000 shares of the company’s stock, valued at approximately $833,000. Simplify Asset Management Inc. owned approximately 0.23% of Zevra Therapeutics as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in ZVRA. Sanctuary Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at $474,000. Vanguard Group Inc. raised its stake in shares of Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after acquiring an additional 58,866 shares in the last quarter. Mystic Asset Management Inc. increased its holdings in Zevra Therapeutics by 11.9% in the second quarter. Mystic Asset Management Inc. now owns 297,947 shares of the company’s stock valued at $1,460,000 after buying an additional 31,650 shares during the last quarter. Retirement Planning Co of New England Inc. increased its holdings in Zevra Therapeutics by 6.5% in the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock valued at $2,246,000 after buying an additional 28,107 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Zevra Therapeutics by 10.7% in the second quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock valued at $1,080,000 after buying an additional 21,231 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Down 1.9 %

ZVRA stock traded down $0.17 during trading on Friday, reaching $8.86. The stock had a trading volume of 134,712 shares, compared to its average volume of 542,768. Zevra Therapeutics, Inc. has a 1-year low of $4.18 and a 1-year high of $9.21. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $466.20 million, a P/E ratio of -4.58 and a beta of 1.93. The firm has a fifty day moving average price of $7.97 and a 200 day moving average price of $6.44.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. During the same quarter in the prior year, the firm earned ($0.15) EPS. On average, equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Analyst Ratings Changes

ZVRA has been the topic of several research reports. Maxim Group raised their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Roth Mkm raised their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group reduced their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.